Transplant Referral Patterns for Patients (Pts) with Newly Diagnosed (ND) Higher-Risk (HR) Myelodysplastic Syndromes (MDS), and European Leukemianet (ELN) 2010 Intermediate-Risk (IR) or Adverse-Risk (AR) Acute Myeloid Leukemia (AML) in the Connect ® MDS/AML Registry
Hematopoietic stem cell transplantation (HSCT) is often indicated and formal transplant referral guidelines exist for pts with AML and HR MDS. However, the proportion of transplant-eligible pts not referred is largely unknown. We therefore assessed HSCT referral patterns, including potential barriers to referral, in pts with ND MDS and AML enrolled in the Connect ® MDS/AML Disease Registry (NCT01688011), a large, US, multicenter, prospective observational cohort study of pts with ND AML (aged ≥ 55 years) or MDS (aged ≥ 18 years).
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Benjamin Tomlinson, Marcos de Lima, Christopher R. Cogle, Michael A. Thompson, David L. Grinblatt, Daniel A. Pollyea, Rami Komrokji, Gail J. Roboz, Michael R. Savona, Mikkael A. Sekeres, E. Dawn Flick, Pavel Kiselev, Chrystal U. Louis, Melissa Nifenecker, Tags: 131 Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Biology | Hematology | Leukemia | Myelodysplastic Syndrome | Stem Cell Therapy | Stem Cells | Study | Transplants